Purpose This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer.
Materials and Methods We studied 7,452 patients who had undergone surgery for breast cancer at Seoul National University Hospital from 2008 to 2015 using the nationwide claims database. Exposure was defined as a recorded prescription of each drug within 12 months before the diagnosis of breast cancer.
Results Patients with prior insulin or statin use were more likely to be older than 50 years at diagnosis and had a higher comorbidity index than those without it (p < 0.01 for both). The hazard ratio (HR) for death with insulin use was 5.7 (p < 0.01), and the effect was attenuated with both insulin and metformin exposure with an HR of 1.2 (p=0.60). In the subgroup analyses, a heightened risk of death with insulin was further prominent with an HR of 17.9 (p < 0.01) and was offset by co-administration of metformin with an HR of 1.3 (p=0.67) in patients with estrogen receptor (ER)–negative breast cancer. Statin use was associated with increased overall mortality only in patients with ER-positive breast cancer with HR for death of 1.5 (p=0.05).
Conclusion Insulin or statin use before the diagnosis of breast cancer was associated with an increase in all-cause mortality. Subsequent analyses suggested that metformin or statin use may have been protective in patients with ER-negative disease, which warrants further studies.
Citations
Citations to this article as recorded by
Repurposing of Metabolic Drugs Metformin and Simvastatin as an Emerging Class of Cancer Therapeutics Santosh Kumar Maurya, Smriti Chaudhri, Shashank Kumar, Sanjay Gupta Pharmaceutical Research.2025; 42(1): 49. CrossRef
Are statins onco- suppressive agents for every type of tumor? A systematic review of literature Luca Filaferro, Fabiana Zaccarelli, Giovanni Francesco Niccolini, Andrea Colizza, Federica Zoccali, Michele Grasso, Massimo Fusconi Expert Review of Anticancer Therapy.2024; 24(6): 435. CrossRef
Investigating the relationship between insulin use and all-cause mortality, breast cancer mortality, and recurrence risk in diabetic patients with breast cancer: A comprehensive systematic review and meta-analysis Marina V. Loktionova, Mahdi Mohammadian, Roya Choopani, Soleiman Kheiri, Abdollah Mohammadian-Hafshejani, Kathleen Bennett PLOS ONE.2024; 19(12): e0314565. CrossRef
Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis Xiaolin Jia, Ye Lu, Zili Xu, Qingqing Mu Frontiers in Oncology.2023;[Epub] CrossRef
Effect of statins use on risk and prognosis of breast cancer: a meta-analysis Guodong Zhao, Yanjun Ji, Qing Ye, Xin Ye, Guanqun Wo, Xi Chen, Xinyi Shao, Jinhai Tang Anti-Cancer Drugs.2022; 33(1): e507. CrossRef
Studying the Cytotoxic Activity of Newly Designed and Synthesized HDAC Inhibitors Derivatives of Pentanoyl Anilide‐5‐Biguanide Othman Makki Sagheer, Mohammed Hassan Mohammed, Jaafar S. Wadi, Zaid O. Ibraheem Macromolecular Symposia.2022;[Epub] CrossRef
Metformin and Breast Cancer: Where Are We Now? Mónica Cejuela, Begoña Martin-Castillo, Javier A. Menendez, Sonia Pernas International Journal of Molecular Sciences.2022; 23(5): 2705. CrossRef
Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression Giorgia Centonze, Dora Natalini, Alessio Piccolantonio, Vincenzo Salemme, Alessandro Morellato, Pietro Arina, Chiara Riganti, Paola Defilippi Frontiers in Oncology.2022;[Epub] CrossRef
Synthesis of gamma biguanides butyric acid analogues as HDAC inhibitors and studying their cytotoxic activity Othman Makki Sagheer, Mohammed Hassan Mohammed, Zaid O. Ibraheem, Jaafar S. Wadi, Mustafa F. Tawfeeq Materials Today: Proceedings.2021; 47: 5983. CrossRef
Statins: a repurposed drug to fight cancer Wen Jiang, Jin-Wei Hu, Xu-Ran He, Wei-Lin Jin, Xin-Yang He Journal of Experimental & Clinical Cancer Research.2021;[Epub] CrossRef
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon International Journal of Clinical Oncology.2021; 26(11): 2004. CrossRef
Purpose
Studies suggest that regular use of metformin may decrease cancer mortality. We investigated the association between diabetes medication use and cancer survival.
Materials and Methods
The current study includes 633 breast, 890 colorectal, 824 lung, and 543 gastric cancer cases identified from participants of two population-based cohort studies in Shanghai. Information on diabetes medication use was obtained by linking to electronic medical records. The associations between diabetes medication use (metformin, sulfonylureas, and insulin) and overall and cancer-specific survival were evaluated using time-dependent Cox proportional hazards models.
Results
After adjustment for clinical characteristics and treatment factors, use of metformin was associated with better overall survival among colorectal cancer patients (hazards ratio [HR], 0.55; 95% confidence interval [CI], 0.34 to 0.88) and for all four types of cancer combined (HR, 0.75; 95% CI, 0.57 to 0.98). Ever use of insulin was associated with worse survival for all cancer types combined (HR, 1.89; 95% CI, 1.57 to 2.29) and for the four cancer types individually. Similar associations were seen for diabetic patients. Sulfonylureas use was associated with worse overall survival for breast or gastric cancer (HR, 2.87; 95% CI, 1.22 to 6.80 and HR, 2.05; 95% CI, 1.09 to 3.84, respectively) among diabetic patients. Similar association patterns were observed between diabetes medication use and cancer-specific survival.
Conclusion
Metformin was associated with improved survival among colorectal cancer cases, while insulin use was associated with worse survival among patients of four major cancers. Further investigation on the topic is needed given the potential translational impact of these findings.
Citations
Citations to this article as recorded by
Effect of Metformin Use on Survival and Recurrence Rate of Gastric Cancer After Gastrectomy in Diabetic Patients: A Systematic Review and Meta-analysis of Observational Studies Mansour Bahardoust, Safa Mousavi, Zahra Deylami Moezi, Mohsen Yarali, Ali Tayebi, Faranak Olamaeian, Adnan Tizmaghz Journal of Gastrointestinal Cancer.2024; 55(1): 65. CrossRef
Antidiabetic Drugs in Breast Cancer Patients Wojciech Garczorz, Agnieszka Kosowska, Tomasz Francuz Cancers.2024; 16(2): 299. CrossRef
Association of metformin and statin uses with the prognosis of colon cancer: a meta-analysis Yanyan Xu, Hao Che, Jiang Liu, Pingjiang Ye European Journal of Cancer Prevention.2024; 33(5): 414. CrossRef
Metformin in combination with chemotherapy increases apoptosis in gastric cancer cells and counteracts senescence induced by chemotherapy Katia Vázquez‑Ibarra, Josefina Sánchez López, Tomás Pineda Razo, José Cruz Lozano, Brenda Ortiz‑Tamayo, Luis Palafox‑Mariscal, Rosa González Arreola, Juan González‑García, Pablo Ortiz-Lazareno Oncology Letters.2024;[Epub] CrossRef
Investigating the relationship between insulin use and all-cause mortality, breast cancer mortality, and recurrence risk in diabetic patients with breast cancer: A comprehensive systematic review and meta-analysis Marina V. Loktionova, Mahdi Mohammadian, Roya Choopani, Soleiman Kheiri, Abdollah Mohammadian-Hafshejani, Kathleen Bennett PLOS ONE.2024; 19(12): e0314565. CrossRef
A Mathematical Model of the Disruption of Glucose Homeostasis in Cancer Patients Noah Salentine, Jonathan Doria, Chinh Nguyen, Gabriella Pinter, Shizhen Emily Wang, Peter Hinow Bulletin of Mathematical Biology.2023;[Epub] CrossRef
Effect of Metformin on the Prognosis of Gastric Cancer Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Based on Retrospective Cohort Studies Lingna Li, Jianing Huang, Tongmin Huang, Jie Yao, Yeyuan Zhang, Meiling Chen, Haojie Shentu, Haiying Lou, Flavia Prodam International Journal of Endocrinology.2023; 2023: 1. CrossRef
Shared Lifestyle-Related Risk Factors of Cardiovascular Disease and Cancer: Evidence for Joint Prevention Farzad Masoudkabir, Noushin Mohammadifard, Arya Mani, Andrew Ignaszewski, Margot K. Davis, Golnaz Vaseghi, Marjan Mansourian, Christopher Franco, Carolyn Gotay, Nizal Sarrafzadegan, Francesco Giallauria The Scientific World Journal.2023; 2023: 1. CrossRef
Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms Li Wang, Zhe Zhang, Eusebio Chiefari Journal of Diabetes Research.2023; 2023: 1. CrossRef
Perspectives of metformin use in endometrial cancer and other gynaecological malignancies Bartłomiej Barczyński, Karolina Frąszczak, Jan Kotarski Journal of Drug Targeting.2022; 30(4): 359. CrossRef
Type 2 Diabetes and all-cause mortality among Spanish women with breast cancer L. Fernández-Arce, N. Robles-Rodríguez, A. Fernández-Feito, A. Llaneza-Folgueras, A. I. Encinas-Muñiz, A. Lana Cancer Causes & Control.2022; 33(2): 271. CrossRef
Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications Guan-Hua Yu, Shuo-Feng Li, Ran Wei, Zheng Jiang, Eusebio Chiefari Journal of Diabetes Research.2022; 2022: 1. CrossRef
Systemic Evaluation of the Effect of Diabetes Mellitus on Breast Cancer in a Mouse Model Nana Wei, Jinmiao Lu, Zhibing Lin, Xiaoyu Wang, Mengmeng Cai, Shengyao Jiang, Xiaoyu Chen, Shilan Zhu, Dong Zhang, Li Cui Frontiers in Oncology.2022;[Epub] CrossRef
The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Esa Läärä, Arja Jukkola, Peeter Karihtala Biomolecules.2022; 12(9): 1301. CrossRef
Metformin protects against diabetes-induced heart injury and dunning prostate cancer model BB Bayrak, P Koroglu, O Karabulut Bulan, R Yanardag Human & Experimental Toxicology.2021; 40(2): 297. CrossRef
Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy Alejandro Schcolnik-Cabrera, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Mandy Juarez, Ariana Vargas-Castillo, Rafael Isaac Ponce-Toledo, Donna Lai, Sheng Hua, Armando R. Tovar, Nimbe Torres, Delia Perez-Montiel, Jose Diaz-Chavez, Alfonso Duenas-Gonzal Scientific Reports.2021;[Epub] CrossRef
Repurposing metformin for the treatment of gastrointestinal cancer Ademar Dantas Cunha Júnior, Arinilda Campos Bragagnoli, Felipe Osório Costa, José Barreto Campello Carvalheira World Journal of Gastroenterology.2021; 27(17): 1883. CrossRef
Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study Jiaojiao Zheng, Giola Santoni, Shao-Hua Xie, Jesper Lagergren British Journal of Cancer.2021; 125(2): 277. CrossRef
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature Chin-Hsiao Tseng Biomolecules.2021; 11(7): 1022. CrossRef
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon International Journal of Clinical Oncology.2021; 26(11): 2004. CrossRef
Progress in understanding of relationship between diabetes and colorectal cancer Guan-Hua Yu, Zheng Jiang World Chinese Journal of Digestology.2021; 29(23): 1323. CrossRef
The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis Y. Shuai, C. Li, X. Zhou Clinical and Translational Oncology.2020; 22(9): 1580. CrossRef
The right place for metformin today Guntram Schernthaner, Gerit-Holger Schernthaner Diabetes Research and Clinical Practice.2020; 159: 107946. CrossRef
Suppressive effects of metformin on colorectal adenoma incidence and malignant progression Min Deng, Siqin Lei, Dongdong Huang, Hui Wang, Shuli Xia, Enping Xu, Yihua Wu, Honghe Zhang Pathology - Research and Practice.2020; 216(2): 152775. CrossRef
Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend
Jing Zhang, Liping Wen, Quan Zhou, Kuifeng He, Lisong Teng Cancer Management and Research.2020; Volume 12: 8545. CrossRef
Does Roux-en-Y Construction Really Bring Benefit of Type 2 Diabetes Mellitus Remission After Gastrectomy in Patients with Gastric Cancer? A Systematic Review and Meta-Analysis Dong Peng, Yu-Xi Cheng, Wei Zhang Diabetes Therapy.2020; 11(12): 2863. CrossRef
Prognosis of Patients with Colorectal Cancer with Diabetes According to Medication Adherence: A Population-Based Cohort Study Sunho Choe, Joonki Lee, Ji Won Park, Seung-Yong Jeong, Young Min Cho, Byung-Joo Park, Aesun Shin Cancer Epidemiology, Biomarkers & Prevention.2020; 29(6): 1120. CrossRef
The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells Alejandro Schcolnik‑Cabrera, Alma Chavez‑Blanco, Guadalupe Dominguez‑Gomez, Mandy Juarez, Donna Lai, Sheng Hua, Armando Tovar, Jose Diaz‑Chavez, Alfonso Duenas‑Gonzalez Oncology Letters.2020; 20(3): 3053. CrossRef
Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs Junichi Kato, Yohei Shirakami, Masahito Shimizu Gastrointestinal Disorders.2019; 1(2): 273. CrossRef
Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer Yong Cui, Wanqing Wen, Tao Zheng, Honglan Li, Yu-Tang Gao, Hui Cai, Mingrong You, Jing Gao, Gong Yang, Wei Zheng, Yong-Bing Xiang, Xiao-Ou Shu American Journal of Epidemiology.2019; 188(8): 1512. CrossRef
Effects of propofol and sevoflurane on blood glucose, hemodynamics, and inflammatory factors of patients with type�2 diabetes mellitus and gastric cancer Jinhui Liu, Li Yang Oncology Letters.2019;[Epub] CrossRef
A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer Audrius Dulskas, Ausvydas Patasius, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte Aging.2019; 11(17): 7197. CrossRef
Purpose
The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo.
Materials and Methods
We investigated the efficacy of combined treatment with TMZ and metformin using cell viability and apoptosis assays. A GBM orthotopic mice model was established by inoculation of 5×105 U87 cells and treatedwith metformin, TMZ, and the combination for 4weeks. Western blotting and immunofluorescence of tumor specimens were analyzed to investigate AMP-activated protein kinase (AMPK) and AKT pathway.
Results
The combination of TMZ and metformin showed higher cytotoxicity than single agents in U87, U251, and A172 cell lines. A combination of high-dose metformin and TMZ showed the highest apoptotic activity. The combination of TMZ and metformin enhanced AMPK phosphorylation and inhibited mammalian target of rapamycin phosphorylation, AKT phosphorylation, and p53 expression. The median survival of each group was 43.6, 55.2, 53.2, 65.2, and 71.3 days for control, metformin treatment (2 mg/25 g/day or 10 mg/25 g/day), TMZ treatment (15 mg/kg/day), combination treatment with low-dose metformin and TMZ, and combination treatment with high-dose metformin and TMZ, respectively. Expression of fatty acid synthase (FASN) was significantly decreased in tumor specimens treated with metformin and TMZ.
Conclusion
The combination of metformin and TMZ was superior to monotherapy using metformin or TMZ in terms of cell viability in vitro and survival in vivo. The combination of high-dose metformin and TMZ inhibited FASN expression in an orthotopic model. Inhibition of FASN might be a potential therapeutic target of GBM.
Citations
Citations to this article as recorded by
Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis Marcio Yuri Ferreira, Eloísa Bittencurt Thomaz de Assis, Savio Batista, Lucca B. Palavani, Gabriel Verly, Eduardo Mendes Corrêa, Lucas Pari Mitre, Jessica Sales de Oliveira, Raphael Bertani, Daniel Antunes Moreno, Allan Dias Polverini World Neurosurgery.2024; 183: 239. CrossRef
Metabolic Contrasts: Fatty Acid Oxidation and Ketone Bodies in Healthy Brains vs. Glioblastoma Multiforme Corina Tamas, Flaviu Tamas, Attila Kovecsi, Alina Cehan, Adrian Balasa International Journal of Molecular Sciences.2024; 25(10): 5482. CrossRef
Metformin and its potential influence on cell fate decision between apoptosis and senescence in cancer, with a special emphasis on glioblastoma Melika Hajimohammadebrahim-Ketabforoush, Alireza Zali, Mohammadreza Shahmohammadi, Amir Ali Hamidieh Frontiers in Oncology.2024;[Epub] CrossRef
Combined metformin and simvastatin therapy inhibits SREBP2 maturation and alters energy metabolism in glioma Xiaolong Qiao, Zixuan Wang, Yinan Chen, Nan Peng, Hongwei Zhang, Chaoshi Niu, Chuandong Cheng Cell Death & Disease.2024;[Epub] CrossRef
GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status Isabele Fattori Moretti, Antonio Marcondes Lerario, Paula Rodrigues Sola, Janaína Macedo-da-Silva, Mauricio da Silva Baptista, Giuseppe Palmisano, Sueli Mieko Oba-Shinjo, Suely Kazue Nagahashi Marie Cancers.2023; 15(3): 587. CrossRef
Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells Corinna Seliger, Lisa Rauer, Anne-Louise Wüster, Sylvia Moeckel, Verena Leidgens, Birgit Jachnik, Laura-Marie Ammer, Simon Heckscher, Katja Dettmer, Markus Riemenschneider, Peter Oefner, Martin Proescholdt, Arabel Vollmann-Zwerenz, Peter Hau International Journal of Molecular Sciences.2023; 24(4): 3199. CrossRef
The Potential Therapeutic Impact of Metformin in Glioblastoma
Multiforme Mehdi Sanati, Samaneh Aminyavari, Hamid Mollazadeh, Ali Motamed-Sanaye, Bahram Bibak, Elmira Mohtashami, Yong Teng, Amir R. Afshari, Amirhossein Sahebkar Current Medicinal Chemistry.2023; 30(7): 857. CrossRef
Development and validation of a GC-MS method for determination of metformin in normal brain and in glioblastoma tissues Giorgia Ailuno, Sara Baldassari, Alice Balboni, Giuliana Drava, Cristina Spalletti, Elena Tantillo, Michele Mazzanti, Federica Barbieri, Stefano Thellung, Tullio Florio, Gabriele Caviglioli Journal of Pharmaceutical and Biomedical Analysis.2023; 234: 115503. CrossRef
Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study) Wan-Soo Yoon, Jong Hee Chang, Jeong Hoon Kim, Yu Jung Kim, Tae-Young Jung, Heon Yoo, Se-Hyuk Kim, Young-Cho Ko, Do-Hyun Nam, Tae Min Kim, Se Hoon Kim, Sung-Hae Park, Youn Soo Lee, Hyeon Woo Yim, Yong-Kil Hong, Seung Ho Yang Discover Oncology.2023;[Epub] CrossRef
Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts Laxmi Dhungel, Cayla Harris, Lauren Romine, Jan Sarkaria, Drazen Raucher Bioengineering.2023; 10(6): 718. CrossRef
Could Metformin and Resveratrol Support Glioblastoma Treatment? A Mechanistic View at the Cellular Level Raghad Sabaawi Ibrahim, Shahad Sabaawi Ibrahim, Ahmed El-Naas, Lenka Koklesová, Peter Kubatka, Dietrich Büsselberg Cancers.2023; 15(13): 3368. CrossRef
Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities Tzu-Jen Kao, Chien-Liang Lin, Wen-Bin Yang, Hao-Yi Li, Tsung-I Hsu Lipids in Health and Disease.2023;[Epub] CrossRef
Drug Repurposing in Pediatric Brain Tumors: Posterior Fossa Ependymoma and Diffuse Midline Glioma under the Looking Glass Tiziana Servidei, Alessandro Sgambato, Donatella Lucchetti, Pierluigi Navarra, Antonio Ruggiero Frontiers in Bioscience-Landmark.2023;[Epub] CrossRef
THERAPEUTIC USE OF METFORMIN IN THYROID CANCER Fatimah Haitham Fathi, Ammar A. Y. Almulathanon, Jehan A. Mohammad Military Medical Science Letters.2022; 91(4): 348. CrossRef
Targeting Oncogenic Rewiring of Lipid Metabolism for Glioblastoma Treatment Haksoo Lee, Dahye Kim, BuHyun Youn International Journal of Molecular Sciences.2022; 23(22): 13818. CrossRef
Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway Jinbiao Xiong, Gaochao Guo, Lianmei Guo, Zengguang Wang, Zhijuan Chen, Yang Nan, Yiyao Cao, Ruilong Li, Xuejun Yang, Jun Dong, Xun Jin, Weidong Yang, Qiang Huang ACS Omega.2021; 6(6): 4289. CrossRef
Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma Silvia Valtorta, Alessia Lo Dico, Isabella Raccagni, Cristina Martelli, Valentina Pieri, Paolo Rainone, Sergio Todde, Bastian Zinnhardt, Elisabetta De Bernardi, Angela Coliva, Letterio S. Politi, Thomas Viel, Andreas H. Jacobs, Rossella Galli, Luisa Ottob Frontiers in Oncology.2021;[Epub] CrossRef
Natural Compounds in Glioblastoma Therapy: Preclinical Insights, Mechanistic Pathways, and Outlook Kevin Zhai, Manaal Siddiqui, Basma Abdellatif, Alena Liskova, Peter Kubatka, Dietrich Büsselberg Cancers.2021; 13(10): 2317. CrossRef
Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review Yuan-Yun Tseng, Tai-Yuan Chen, Shih-Jung Liu International Journal of Nanomedicine.2021; Volume 16: 4597. CrossRef
In Vitro and In Vivo Enhancement of Temozolomide Effect in Human Glioblastoma by Non-Invasive Application of Cold Atmospheric Plasma Vikas Soni, Manish Adhikari, Hayk Simonyan, Li Lin, Jonathan H. Sherman, Colin N. Young, Michael Keidar Cancers.2021; 13(17): 4485. CrossRef
Landscape of the oncogenic role of fatty acid synthase in human tumors Xulei Huo, Lairong Song, Da Li, Ke Wang, Yali Wang, Feng Chen, Liwei Zhang, Liang Wang, Junting Zhang, Zhen Wu Aging.2021; 13(23): 25106. CrossRef
Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer Sonia A. Allen, Sandipan Datta, Jose Sandoval, Alexey Tomilov, Thomas Sears, Kevin Woolard, James M. Angelastro, Gino A. Cortopassi Mitochondrion.2020; 50: 19. CrossRef
Metformin treatment decreases the expression of cancer stem cell marker CD44 and stemness related gene expression in primary oral cancer cells Shankargouda Patil Archives of Oral Biology.2020; 113: 104710. CrossRef
Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil Neslisah Barlak, Fatma Sanli, Ozel Capik, Elanur Tuysuz, Elanur Aydın Karatas, Hasan Turkez, Omer Faruk Karatas Clinical Cancer Drugs.2020; 7(1): 16. CrossRef
An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin Marta Calvo Tardón, Eliana Marinari, Denis Migliorini, Viviane Bes, Stoyan Tankov, Emily Charrier, Thomas A McKee, Valérie Dutoit, Pierre-Yves Dietrich, Erika Cosset, Paul R Walker Biology.2020; 9(9): 264. CrossRef
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead Rashmi R. Shah, Peter D. Stonier Journal of Clinical Pharmacy and Therapeutics.2019; 44(1): 6. CrossRef
Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity Federica Barbieri, Ivan Verduci, Valentina Carlini, Gianluigi Zona, Aldo Pagano, Michele Mazzanti, Tullio Florio Frontiers in Oncology.2019;[Epub] CrossRef
DrugR+: A comprehensive relational database for drug repurposing, combination therapy, and replacement therapy Yosef Masoudi-Sobhanzadeh, Yadollah Omidi, Massoud Amanlou, Ali Masoudi-Nejad Computers in Biology and Medicine.2019; 109: 254. CrossRef
Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells Alessia Lo Dico, Silvia Valtorta, Luisa Ottobrini, Rosa Maria Moresco Frontiers in Oncology.2019;[Epub] CrossRef
Repurposing drugs for the treatment of glioma Chengming Xu, Yaodong Zhao, Congyan Wu, Lei Li Glioma.2019; 2(4): 159. CrossRef
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway Chung-Ching Chio, Yu-Ting Tai, Mahendravarman Mohanraj, Shing-Hwa Liu, Shun-Tai Yang, Ruei-Ming Chen Phytomedicine.2018; 49: 41. CrossRef
Pleiotropic Effects of Metformin on Cancer Hans-Juergen Schulten International Journal of Molecular Sciences.2018; 19(10): 2850. CrossRef
Metformin attenuates cells stemness and epithelial‑mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β‑catenin pathway Chu Zhang, Yuchen Wang Molecular Medicine Reports.2018;[Epub] CrossRef
Purpose
The purpose of this study was to observe the effects of metformin on human esophageal cancer cell and to investigate its possible mechanisms.
Materials and Methods
Cell viability was detected by using a Cell Counting Kit-8, while cell cycle and apoptosis were assessed by flow cytometry and western blot was used to measure the expression of the related proteins. RNAi was used to knockout pyruvate kinase muscle isozyme 2 (PKM2). An Eca109 tumor model was established to evaluate the antitumor effect in vivo. Immunohistochemistry was determined based on the expression of PKM2 and Bim in tumor tissues. Tunnel was used to assess tumor cell apoptosis.
Results
Esophageal cancer cells viability was reduced after metformin treatment. The cell cycle was arrested in the G0/G1 phase, apoptosis was induced, caspase 3 was activated, caspase 9 was downregulated, and the pro-apoptotic protein Bim increased. Further study revealed that metformin could suppress the expression of insulin-like growth factor 1 receptor and its downstream proteins, phosphoinositide 3-kinase (PI3K), protein kinase B (AKT/PKB), phosphorylation of AKT (pAKT), mammalian target of rapamycin (mTOR), p70S6K, and PKM2. Insulin-like growth factor 1 partly reversed metfromin-induced apoptosis and attenuated the repression effect of metfomin to PI3K, pAKT, and PKM2. Knockout PKM2 resulted in the activation of caspase 3, down-regulation of caspase 9, and increased expression of Bim. In the Eca109 xenograft model, metformin significantly reduced tumor growth. Furthermore, we found that metformin treatment increased the rate of apoptosis, down-regulation of PKM2, and up-regulation of Bim in tumor tissues.
Conclusion
Metformin restrained esophageal cancer cell proliferation partly by suppressing the PI3K/AKT/mTOR pathway.
Citations
Citations to this article as recorded by
Metformin and the PI3K/AKT signaling pathway: implications for cancer, cardiovascular, and central nervous system diseases Hemin Ashayeri Ahmadabad, Somayeh Mohammadi Panah, Hojat Ghasemnejad‐Berenji, Shabnam Ghojavand, Morteza Ghasemnejad-Berenji, Mohammad Rafi Khezri Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(2): 1035. CrossRef
SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase Xiaobin Wang, Shulin Li, Zichen Li, Zhuona Lin, Zhifeng Wang Lipids in Health and Disease.2025;[Epub] CrossRef
Exploring the Effects of Metformin on the Body via the Urine Proteome Yuzhen Chen, Haitong Wang, Minhui Yang, Ziyun Shen, Youhe Gao Biomolecules.2025; 15(2): 241. CrossRef
Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights Stavros P. Papadakos, Alexandra Argyrou, Vasileios Lekakis, Konstantinos Arvanitakis, Polyxeni Kalisperati, Ioanna E. Stergiou, Ippokratis Konstantinidis, Dimitrios Schizas, Theocharis Koufakis, Georgios Germanidis, Stamatios Theocharis International Journal of Molecular Sciences.2024; 25(5): 2978. CrossRef
Ianus Bifrons: The Two Faces of Metformin Umberto Goglia, Iderina Hasballa, Claudia Teti, Mara Boschetti, Diego Ferone, Manuela Albertelli Cancers.2024; 16(7): 1287. CrossRef
Changes in the expression of cancer- and metastasis-related genes and proteins after metformin treatment under different metabolic conditions in endometrial cancer cells Carsten Lange, Jana Brüggemann, Theresa Thüner, Julia Jauckus, Thomas Strowitzki, Ariane Germeyer Heliyon.2023; 9(6): e16678. CrossRef
Metformin Induces a Caspase 3-Unrelated Apoptosis in Human Colorectal Cancer Cell Lines HCT116 and SW620 Bustanur Rosidi, Diana Priyatno, Teguh Pribadi Putra, Irawan Yusuf Cancer Management and Research.2023; Volume 15: 475. CrossRef
Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models Mirian Galliote Morale, Rodrigo Esaki Tamura, Ileana Gabriela Sanchez Rubio Biomolecules.2022; 12(3): 357. CrossRef
Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma Nobufumi Sekino, Masayuki Kano, Sohei Kobayashi, Kentaro Murakami, Haruhito Sakata, Takeshi Toyozumi, Satoshi Endo, Yasunori Matsumoto, Hiroshi Suito, Masahiko Takahashi, Ryota Otsuka, Masaya Yokoyama, Tadashi Shiraishi, Koichiro Okada, Toshiki Kamata, Ta Oncology.2022; 100(5): 267. CrossRef
The Role of PKM2 in the Regulation of Mitochondrial Function: Focus on Mitochondrial Metabolism, Oxidative Stress, Dynamic, and Apoptosis. PKM2 in Mitochondrial Function Jing Gao, Yuwei Zhao, Tao Li, Xueqi Gan, Haiyang Yu, Daniel Lopez Malo Oxidative Medicine and Cellular Longevity.2022; 2022: 1. CrossRef
Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER–Medicare Analysis Holli A. Loomans-Kropp, Matthew Chaloux, Ellen Richmond, Asad Umar Cancer Prevention Research.2021; 14(2): 195. CrossRef
Advances and challenges in the treatment of esophageal cancer Shiming He, Jian Xu, Xiujun Liu, Yongsu Zhen Acta Pharmaceutica Sinica B.2021; 11(11): 3379. CrossRef
Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line Carsten Lange, Amanda Machado Weber, Ronny Schmidt, Christoph Schroeder, Thomas Strowitzki, Ariane Germeyer, Jae-Wook Jeong PLOS ONE.2021; 16(3): e0248103. CrossRef
Glucose and fatty acid metabolism involved in the protective effect of metformin against ulipristal-induced endometrial changes in rats Marwa S. Hamza, Eman Ramadan, Salama A. Salama Scientific Reports.2021;[Epub] CrossRef
12-Epi-Napelline Inhibits Leukemia Cell Proliferation via the PI3K/AKT Signaling Pathway In Vitro and In Vivo Jia Han, Wei Hou, Bi-qing Cai, Fan Zhang, Jian-cai Tang, Xing Li Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1. CrossRef
Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis Lisha Li, Dongfeng Song, Ling Qi, Mingxia Jiang, Yiming Wu, Junqing Gan, Kui Cao, Yanjing Li, Yuxian Bai, Tongsen Zheng Cancer Letters.2021; 520: 143. CrossRef
Retracted: Silence of cZNF292 suppresses the growth, migration, and invasion of human esophageal cancer Eca‐109 cells via upregulating miR‐206 Zengjia Liu, Guiju Hu, Yan Zhao, Zuorun Xiao, Mingzhe Yan, Mei Ren Journal of Cellular Biochemistry.2020; 121(3): 2354. CrossRef
Metformin Promotes Axon Regeneration after Spinal Cord Injury through Inhibiting Oxidative Stress and Stabilizing Microtubule Haoli Wang, Zhilong Zheng, Wen Han, Yuan Yuan, Yao Li, Kailiang Zhou, Qingqing Wang, Ling Xie, Ke Xu, Hongyu Zhang, Huazi Xu, Yanqing Wu, Jian Xiao Oxidative Medicine and Cellular Longevity.2020; 2020: 1. CrossRef
The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer Mingxia Jiang, Ling Qi, Lisha Li, Yanjing Li Cell Death Discovery.2020;[Epub] CrossRef
Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation Cong Zhang, Junjie Hu, Lei Sheng, Ming Yuan, Yong Wu, Liang Chen, Guohua Zheng, Zhenpeng Qiu Toxicology and Applied Pharmacology.2019; 365: 51. CrossRef
Enhanced penetration and cytotoxicity of metformin and collagenase conjugated gold nanoparticles in breast cancer spheroids Elaheh Dalir Abdolahinia, Samad Nadri, Reza Rahbarghazi, Jaleh Barar, Ayoub Aghanejad, Yadollah Omidi Life Sciences.2019; 231: 116545. CrossRef
Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms Mari C Vázquez-Borrego, Antonio C Fuentes-Fayos, Aura D Herrera-Martínez, Fernando L-López, Alejandro Ibáñez-Costa, Paloma Moreno-Moreno, María R Alhambra-Expósito, Ana Barrera-Martín, Cristóbal Blanco-Acevedo, Elena Dios, Eva Venegas-Moreno, Juan Soliver The Journal of Clinical Endocrinology & Metabolism.2019; 104(8): 3501. CrossRef
Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo Jianwen Ye, Lei Qi, Kunlun Chen, Renfeng Li, Shengping Song, Chuang Zhou, Wenlong Zhai International Journal of Oncology.2019;[Epub] CrossRef
AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-κB axis Bin Zheng, Li Geng, Li Zeng, Fangfang Liu, Qiaojia Huang Cellular Signalling.2018; 45: 122. CrossRef
Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma Nobufumi Sekino, Masayuki Kano, Yasunori Matsumoto, Haruhito Sakata, Yasunori Akutsu, Naoyuki Hanari, Kentaro Murakami, Takeshi Toyozumi, Masahiko Takahashi, Ryota Otsuka, Masaya Yokoyama, Tadashi Shiraishi, Koichiro Okada, Isamu Hoshino, Keiko Iida, Aki Cancer Science.2018; 109(4): 1066. CrossRef
Down‐regulation of intracellular anti‐apoptotic proteins, particularly c‐FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL Ali Hassanzadeh, Majid Farshdousti Hagh, Mohammad Reza Alivand, Ali Akbar Movassaghpour Akbari, Karim Shams Asenjan, Raedeh Saraei, Saeed Solali Journal of Cellular Physiology.2018; 233(10): 6470. CrossRef
Interaction Between Prediabetes and the ABO Blood Types in Predicting Postsurgical Esophageal Squamous Cell Carcinoma-Specific Mortality: The FIESTA Study Guohui Fan, Dan Hu, Xinran Zhang, Feng Peng, Xiandong Lin, Gang Chen, Binying Liang, Hejun Zhang, Yan Xia, Xiongwei Zheng, Jianzheng Jie, Wenquan Niu Frontiers in Oncology.2018;[Epub] CrossRef
Obesity, Diabetes and Gastrointestinal Malignancy: The role of Metformin and other Anti-diabetic Therapy McFarlane Samy I Global Journal of Obesity, Diabetes and Metabolic Syndrome.2018; : 008. CrossRef
Purpose Metformin is associated with an anticancer effect. However, the effects of metformin in rectal cancer are controversial. This study investigated the impact of metformin on the survival of patients with diabetes mellitus and nonmetastatic rectal cancer who underwent curative surgery.
Materials and Methods The database was provided by the Korea Center Cancer Registry and National Health Insurance Service of the Republic of Korea. A cohort of patients with newly diagnosed rectal cancer between 2005 and 2011 was identified. Drug exposure was defined as receiving the oral hypoglycemic agent for at least 90 days over the period from 6 months before the initial diagnosis of rectal cancer to the last follow-up.
Results A total of 4,503 patients were prescribed oral hypoglycemic agents and classified as the diabetic group, of which 3,694 patients received metformin for at least 90 days. Unadjusted analyses showed a significantly higher overall survival (hazard ratio, 0.596; 95% confidence interval, 0.506 to 0.702) and rectal cancer-specific survival (hazard ratio, 0.621; 95% confidence interval, 0.507 to 0.760) in the metformin group than in the nonmetformin group. The adjusted overall survival (hazard ratio, 0.631; 95% confidence interval, 0.527 to 0.755) and cancer-specific survival (hazard ratio, 0.598; 95% confidence interval, 0.479 to 0.746) in the group with a medication possession ratio of 80% or greater was significantly higher than in the group with a medication possession ratio of less than 80%.
Conclusion Metformin use is associated with overall and cancer-specific survival in diabetic patients with a nonmetastatic rectal cancer treated with a curative resection.
Citations
Citations to this article as recorded by
Metformin Does not Affect Outcomes in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Therapy and Resection Swati Sonal, Chloe Boudreau, Hiroko Kunitake, Robert N. Goldstone, Grace C. Lee, Christy E. Cauley, Liliana G. Bordeianou, Todd D. Francone, Rocco Ricciardi, David L. Berger The American Surgeon™.2024; 90(4): 858. CrossRef
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences Guglielmina Froldi Pharmaceuticals.2024; 17(4): 478. CrossRef
Type II diabetes and metformin use does not affect colorectal cancer prognosis Mehrnoosh Shahrivar, Caroline E. Dietrich, Bengt Glimelius, Deborah Saraste, Anna Martling, Christian Buchli, Caroline Nordenvall International Journal of Cancer.2024;[Epub] CrossRef
Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome Ji Soo Park, Soo Jin Moon, Hyung Seok Park, Sang-Hoon Cho Preventive Medicine Reports.2024; 48: 102928. CrossRef
Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model Mineyuki Tojo, Hideyo Miyato, Koji Koinuma, Hisanaga Horie, Hidenori Tsukui, Yuki Kimura, Yuki Kaneko, Hideyuki Ohzawa, Hironori Yamaguchi, Kotaro Yoshimura, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama Scientific Reports.2022;[Epub] CrossRef
Clinicopathological Characteristics and Overall 5-Year Survival of Colorectal Cancer: A Retrospective Study Rahaf Almuhanna, Fatma Al-Thoubaity, Khadijah Almalki, Nada Algarni, Renad Hamad, Toleen Makhtoum Medical Sciences.2022; 10(3): 42. CrossRef
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu Medicine.2022; 101(49): e31799. CrossRef
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon International Journal of Clinical Oncology.2021; 26(11): 2004. CrossRef
Suppressive effects of metformin on colorectal adenoma incidence and malignant progression Min Deng, Siqin Lei, Dongdong Huang, Hui Wang, Shuli Xia, Enping Xu, Yihua Wu, Honghe Zhang Pathology - Research and Practice.2020; 216(2): 152775. CrossRef
Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences Yunzi Wang, Jingping Xiao, Yuanyu Zhao, Shijuan Du, Jiang Du International Journal of Colorectal Disease.2020; 35(5): 827. CrossRef
Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study Wen‐Kuan Huang, Shu‐Hao Chang, Hung‐Chih Hsu, Wen‐Chi Chou, Tsai‐Sheng Yang, Jen‐Shi Chen, John Wen‐Cheng Chang, Yung‐Chang Lin, Chang‐Fu Kuo, Lai‐Chu See International Journal of Cancer.2020; 147(7): 1904. CrossRef
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression Cheng-Ann Winston Ng, Amy Aimei Jiang, Emma Min Shuen Toh, Cheng Han Ng, Zhi Hao Ong, Siyu Peng, Hui Yu Tham, Raghav Sundar, Choon Seng Chong, Chin Meng Khoo International Journal of Colorectal Disease.2020; 35(8): 1501. CrossRef
Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus Akira Saito, Joji Kitayama, Hisanaga Horie, Koji Koinuma, Hideyuki Ohzawa, Hironori Yamaguchi, Hiroshi Kawahira, Toshiki Mimura, Alan Kawarai Lefor, Naohiro Sata Cancer Science.2020; 111(11): 4012. CrossRef
Patterns of Rectal Cancer Radiotherapy Adopting Evidence-Based Medicine: An Analysis of the National Database from 2005 to 2016 Hae Jin Park, Sanghyun Cho, Yoon Kim Cancer Research and Treatment.2018; 50(3): 975. CrossRef
UEG Week 2018 Poster Presentations
United European Gastroenterology Journal.2018;[Epub] CrossRef